We Are The Cure Blog | Canine Cancer Information

Lymphoma in dogs is one of the most common cancers. While between 80 and 90% of dogs will achieve a complete remission, with conventional chemotherapy protocols the median time to loss of first remission is between 8 and 10 months with median overall survivals ranging between 12 and 14 months. Only about 5% of dogs will be alive at two years. The last major breakthrough for the treatment of canine lymphoma was the addition of doxorubicin to combination chemotherapy protocols around 30 years ago. New therapies to break through this ceiling are desperately needed.

We have recently begun enrolling dogs with relapsed lymphoma in a new clinical trial to evaluate a new type of chemotherapy treatment. We are evaluating response and toxicity. Working closely with the human medical school we have developed a nanoparticle targeting agent. This molecule targets dog lymphoma cells and brings conventional chemotherapy agents to the cancer cells. This has the potential of making therapy for lymphoma both more effective and less toxic.

This work is funded by a grant from the National Canine Cancer Foundation. At the conclusion of the trial we will make more information on this exciting new treatment available on the website

Tags: Cancer, Canine Cancer Research

This entry was posted on Tuesday, March 3rd, 2009 at 5:41 pm and is filed under Cancer, Cancer Research, Canine Cancer, Dogs. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.